- Home
- AGEN
AGEN
Agenus Inc.
as 12-20-2024 4:00pm EST
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
| Founded: | 1994 | Country: | United States |
| Employees: | N/A | City: | LEXINGTON |
| Market Cap: | 96.2M | IPO Year: | 2000 |
| Target Price: | $10.50 | AVG Volume (30 days): | 566.5K |
| Analyst Decision: | Buy | Number of Analysts: | 3 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -11.09 | EPS Growth: | N/A |
| 52 Week Low/High: | $2.50 - $19.69 | Next Earning Date: | 11-12-2024 |
| Revenue: | $160,427,000 | Revenue Growth: | 59.00% |
| Revenue Growth (this year): | -29.44% | Revenue Growth (next year): | 36.13% |
Latest Agenus Inc. News
AGEN Breaking Stock News: Dive into AGEN Ticker-Specific Updates for Smart Investing
Business Wire
4 days ago
Agenus Announces Five Presentations at ASCO GI Highlighting BOT/BAL Activity Across Colorectal and Gastric Cancers
BioPharma Dive
16 days ago
AstraZeneca, Daiichi build cancer drug case; Amgen invests $1B
Business Wire
17 days ago
Agenus Announces Strategic Realignment to Focus on Core Programs and Significantly Reduce Costs
Benzinga
25 days ago
Agenus Gets $22M Mortgage, Plans Strategic Realignment To Focus On Colorectal Cancer Drug Development
MT Newswires
25 days ago
Agenus Secures $22 Million Mortgage, Plans Operational Realignment; Shares Jump
Business Wire
25 days ago
Agenus Secures $22 Million Mortgage and Announces Strategic Operational Realignment
Zacks
a month ago
Agenus (AGEN) Loses -41.56% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Zacks
a month ago
Agenus (AGEN) Loses -41.13% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
Compare AGEN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "AGEN Agenus Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.